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Title: Effect of remote ischemic conditioning on clinical outcomes in patients presenting 
with a ST-segment elevation myocardial infarction undergoing primary percutaneous 
coronary intervention 
 
Standfirst: The rationale and study design for the multicentre randomised controlled 
CONDI2/ERIC-PPCI study 
 
 
Aim  
 
Ischemic heart disease (IHD) is the leading cause of death and disability worldwide. For   
patients presenting with an acute ST-segment elevation myocardial infarction (STEMI)  
treated by primary percutaneous coronary intervention (PPCI), new therapies are required to  
reduce myocardial infarct (MI) size, in order to preserve left ventricular ejection fraction,  
prevent the onset of heart failure and improve patient survival. In this regard, remote  
ischemic conditioning (RIC) using transient ischemia/reperfusion of the arm has been  
reported to reduce MI size in STEMI patients undergoing PPCI. Whether RIC can improve  
long-term clinical outcomes in this patient group is unknown, and is investigated in the  
CONDI2/ERIC-PPCI trial. 
 
Methods  
 
The CONDI2/ERIC-PPCI study is a European multicentre (Denmark, Serbia, Spain, and 
United Kingdom) randomised controlled clinical trial of 4300 STEMI patients undergoing 
PPCI. Eligible patients will be randomised to receive either RIC (four-5 min 
inflations/deflations of cuff placed on upper arm) or control prior to PPCI. The primary 
endpoint of the study will be cardiac death and heart failure hospitalisation. Secondary 
endpoints will include rates of all-cause death, coronary revascularisation, re-infarction, stroke 
at 30 days and 12 months, TIMI flow post-PPCI, ST-segment resolution on ECG, and quality 
of life. MI size will bedetermined in cardiac enzyme and cardiac MRI sub-studies. 
 
Conclusion   
 
The CONDI2/ERIC-PPCI study will determine whether RIC can improve long-term clinical  
outcomes in STEMI patients undergoing PPCI. 
The CONDI2/ERIC-PPCI trial is registered at www.clinicaltrials.gov (Identifiers: 
NCT01857414 and NCT02342522).  
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Introduction 
Ischemic heart disease (IHD) is the leading cause of death and disability in Europe and 
worldwide. In patients presenting with an acute ST-elevation myocardial infarction (STEMI), 
early myocardial reperfusion using primary percutaneous coronary intervention (PPCI) is the 
most effective treatment for limiting myocardial infarct (MI) size and improving clinical 
outcomes. However, despite timely PPCI, the morbidity and mortality of STEMI patients 
remain significant – as such novel therapeutic strategies are required to reduce MI size in order 
to preserve left ventricular (LV) ejection fraction, prevent the onset of heart failure and improve 
patient survival.  
In this respect, the heart can be protected against acute lethal ischemia/reperfusion 
injury (IRI) by applying cycles of brief non-lethal ischemia/reperfusion to an organ or tissue 
remote from the heart – a phenomenon called remote ischemic conditioning (RIC) 1-3. 
Interestingly, RIC can be induced non-invasively by simply inflating and deflating a blood 
pressure cuff placed on the upper arm, an intervention that has been reported to reduce MI size 
in several proof-of-concept clinical studies 4-10. Whether RIC can improve long-term clinical 
outcomes in this patient group is unknown and is the objective of the CONDI-2/ERIC-PPCI 
study. 
 
METHODS 
Study design 
The CONDI2/ERIC-PPCI study is a European (Denmark, Serbia, Spain and UK) prospective 
randomised controlled clinical trial of 4,300 participants. The study will be conducted in 
accordance with the Declaration of Helsinki and has been approved by the Ethics committees 
of the respective countries. All patients will provide informed written consent.  
 
Study population 
Inclusion criteria 
i. Onset of symptoms within 12 hours 
ii. Age≥18 years  
iii. Suspected STEMI (ST-elevation at the J-point in two contiguous leads with the cut-off 
points: ≥0.2 millivolt (mV) in men or ≥0.15 mV in women in leads V2-V3 and/or ≥0.1 
mV in other leads) 
 
Exclusion criteria 
i. Known ineligibility for PPCI 
ii. Previous coronary artery bypass graft surgery 
iii. Myocardial infarction (MI) within the previous 30 days  
iv. Treatment with thrombolysis within the previous 30 days 
v. Left bundle branch block (LBBB) 
vi. Patients treated with therapeutic hypothermia 
vii. Conditions precluding use of RIC (paresis of upper limb, use of an arterio-venous 
shunt) 
viii. Life expectancy of less than 1 year due to non-cardiac pathology 
 
Randomisation  
Patients will be randomised to either RIC or control. Randomisation will be coordinated 
centrally via a secure website and will be stratified by centre using random permuted blocks. 
The PPCI operator, medical staff and the research investigator collecting and analysing the data 
will be blinded to the treatment allocation. 
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Trial interventions  
An automated CellAegis AutoRIC™ cuff device www.cellaegisdevices.com will be used to 
deliver the RIC protocol. The RIC and sham RIC intervention will be delivered prior to PPCI 
and according to local conditions - where ambulance transit times allow, the trial intervention 
will be delivered in the ambulance (Denmark and Spain), but where ambulance transit times 
are short the trial intervention will be delivered on immediate arrival at the PPCI center (Serbia 
and UK).   
 
RIC intervention 
An automated autoRIC™ cuff will be placed on the upper arm and inflated to 200mmHg for 5 
minutes and then deflated for 5 minutes, a cycle which will be undertaken 4 times in total. For 
patients presenting with a systolic blood pressure (SBP) ≥175mmHg, a manual blood pressure 
cuff will be used and inflated to 25 mmHg above systolic blood pressure. 
 
Sham RIC intervention  
In sites where the trial intervention is applied on arrival at the PPCI centre (Serbia and UK), an 
AutoRIC™ cuff visually identical to that used in the RIC protocol will be placed on the upper 
arm and a simulated RIC protocol applied. Inflation will be simulated and held for 5 minutes, 
deflation will then be simulated and held for five minutes, a cycle which will be undertaken 4 
times in total. For feasibility and logistical reasons, in those patients recruited and randomised 
in the ambulance no sham RIC control will be delivered (Denmark and Spain).  
As the RIC / sham RIC protocol lasts 35 minutes, in cases where the door-PPCI time is 
less than 35 min, the RIC / sham RIC protocol may overlap with the beginning of the PPCI 
procedure. Under no circumstances will the RIC protocol delay the onset of PPCI. 
 
Study endpoints 
Primary endpoint 
The primary endpoint will be cardiac death and heart failure hospitalisation at 12 months. These 
events will be validated by an independent event validation committee (EVC). Heart failure 
hospitalisation will be defined as an event that meets the following criteria (in brief)11: (i) The 
patient is admitted to the hospital with a primary diagnosis of heart failure (HF); (ii) The patient 
exhibits documented new or worsening symptoms due to HF on presentation; (iii) the patient 
has objective evidence of new or worsening HF; and (iv) the patient receives initiation or 
intensification of treatment specifically for HF. 
 
Secondary endpoints  
i. Rates of cardiac death and heart failure hospitalisation at 30 days.  
ii. Rates of all-cause death, coronary revascularization,, re-infarction, stroke at 30 days 
and 12 months 
iii. TIMI flow post-PPCI 
iv. ST-segment resolution on 90 minute ECG 
v. Enzymatic MI size will be assessed from a 48 hour area-under-the-curve (AUC) high-
sensitive Troponin-T (hsTrop-T) using blood samples collected at time 0, 6, 12, 24, and 
48 hours in a 400 patient substudy. 
vi. MI size will be measured by cardiac magnetic resonance (CMR) scan performed at 6 
months in a 250 patient substudy.  
 
Sample size determination 
The primary combined endpoint will be cardiac death and heart failure hospitalisation at 12 
months. According to the UK NIAP 2008 database, cardiac mortality at 12 months ranged from 
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5.8%-16.7% depending on the call to balloon time, with the overall 12 month death rate of 
8.7% for all PPCI patients. In a recent Danish clinical study post-PPCI, the one-year mortality 
was 9.4% and the cumulative risk of readmission with heart failure was 8%12. In another, non-
UK based, clinical study, the incidence of heart failure hospitalisation was 12.7% at 12 months 
post-PPCI13. We have based our power calculations on these published studies, accounting for 
the marked improvements in clinical outcomes in the contemporary era by using much more 
conservative event rates. As a conservative estimate we will use a combined cardiac death and 
heart failure hospitalisation event rate of 11.0% at 12 months for all-comer STEMI patients. 
We have estimated the effect size to be a 25% relative reduction in the event rate. The rationale 
for this is based on proof-of-concept clinical studies in which RIC have reported 30% 
reductions in MI size 4-10. To demonstrate a 25% reduction in the primary composite endpoint 
in the RIC-treated group (from 11.0% to 8.25%), with 80% power and at the 5% significance 
level, will require 1,805 patients per treatment arm which equates to 3,610 patients in total. 
Therefore, we will need to recruit 4,300 STEMI patients (conservatively allowing for a 15% 
drop-out rate at 12 months).  
 
Statistical Analysis 
A detailed statistical analysis plan will be produced prior to un-blinding of any data. The 
primary analysis will be a comparison of the cardiac death or heart failure hospitalisation event 
rate one year after randomisation between the RIC and the control arms of the trial amongst all 
STEMI patients. Hazard ratios and confidence intervals will be calculated using Cox 
proportional hazards modelling and Kaplan-Meier curves will be produced. In addition risk 
differences at one year will also be calculated together with 95% confidence intervals. The 
results for the individual components of the primary endpoint will also be presented together 
with other time-to-event secondary endpoints such as cardiac death or heart failure 
hospitalisation at 30 days. Differences in means (continuous variables) together with 95% 
confidence intervals will be calculated using linear regression models and analysis of 
covariance techniques where appropriate. The primary analysis will be performed on an 
intention-to-treat basis i.e. by including all patients where possible according to the group to 
which they were randomised irrespective of whether they received the intervention as allocated. 
A secondary per-protocol analysis will be undertaken including only patients who receive the 
allocated intervention as intended.  
 
Clinical study monitoring and data management  
The Clinical Trials Units at the London School of Hygiene and Tropical Medicine, London, 
UK and the Department of Cardiology and Department of Clinical Epidemiology, Aarhus 
University Hospital will oversee the trial. The nominated sponsor of the ERIC-PPCI arm will 
be University College London, and of the CONDI2 arm will be the University of Aarhus.  
 
Discussion 
The phenomenon of RIC was initially described in 1993 by Przyklenk et al 1 in a seminal 
experimental study demonstrating that the cardioprotective effect of ischemic preconditioning 
could extend from one coronary artery territory to another. The concept of RIC was then 
extended to organs and tissue remote from the heart (reviewed in {Hausenloy, 2008 3153 /id}). 
Its translation into the clinical setting were facilitated by the discovery in 2002 by Kharbanda 
et al 14 that the RIC stimulus could be induced non-invasively in human volunteers by simply 
inflating and deflating a blood pressure cuff placed on the upper arm. Since then RIC has been 
investigated as a cardioprotective strategy in a number of clinical settings including cardiac 
bypass surgery 15-20, elective PCI 21;22, and stroke 23 with mixed results. Despite intensive 
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investigation, the mechanisms underlying RIC remain unclear but have been attributed to a 
neuro-hormonal pathway linking the RIC-treated organ or tissue to the target organ 2;3;24.  
RIC has also been investigated in the setting of STEMI in five small proof-of-concept 
clinical studies 4;6-9. The first study by Botker et al 4;25 reported that RIC (four-5 minute upper 
arm cuff inflations and deflations) administered in the ambulance by paramedics on route to 
the PPCI centre, significantly increased mean salvage index from 0·57 in control to 0.69 with 
RIC at 30 days (as measured by myocardial single-photon emission computerized tomography 
(SPECT)). In a post-hoc subgroup analysis of patients presenting with a left anterior 
descending coronary artery STEMI, myocardial salvage was increased further, and there was 
a significant reduction in final MI size and improvement in LV ejection fraction at 30 days 4;25. 
Interestingly, 4-year follow-up of this patient cohort revealed less all-cause death in those 
patients given RIC at the time of their PPCI, although this study was not prospectively designed 
or powered to investigate long-term outcomes10. Rentoukas et al 6 demonstrated in 96 patients 
that RIC (three 4-minute upper arm cuff inflations and deflations) administered at the PPCI 
centre improved ST-segment resolution and reduced MI size assessed by biomarker release 
when compared to control. Crimi et al 7 found that RIC administered after PPCI  reduced 
biochemical infarct size and was also associated with an improvement of T2-weighted oedema 
volume and >50% ST-segment resolution in STEMI patients undergoing PPCI. White et al 8 
found that RIC initiated on arrival at the PPCI centre reduced MI size by 27% (measured by 
CMR) in STEMI patients. Finally, Prunier et al 9 confirmed the MI-limiting effects of RIC, but 
failed to demonstrate an additive cardioprotective effect with ischemic postconditioning. 
Therefore, it is well-established that RIC can reduce MI size in STEMI patients treated by 
PPCI, but whether this beneficial effect translates to improved clinical outcomes is not known 
and will be investigated in the CONDI2/ERIC-PPCI study.  
In conclusion, the CONDI2/ERIC-PPCI study will determine whether limb RIC, a non-
invasive low-cost therapeutic intervention can improve long-term clinical outcomes in STEMI 
patients treated by PPCI.  
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